We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease
The Fast Track designation accelerates troculeucel’s path to U.S. FDA submission for the treatment of patients with moderate Alzheimer’s disease. NKGen will benefit from increased FDA interactions, ...
Fintel on MSN1d
Goldman Sachs Initiates Coverage of Silence Therapeutics plc - Depositary Receipt () (SLN) with Sell Recommendation
Fintel reports that on February 11, 2025, Goldman Sachs initiated coverage of Silence Therapeutics plc - Depositary Receipt ( ...
PMLiVE2h
Novartis to expand cardiovascular pipeline with $3.1bn Anthos acquisition
Novartis has announced that it will be expanding its late-stage cardiovascular pipeline by acquiring Anthos Therapeutics for ...
Business Wire1d
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
This mimics natural Factor XI deficiency ... the development and commercialization of Anthos Therapeutics’ product candidates and the potential benefits of abelacimab. All statements, other than ...
KBC Group NV Boosts Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
KBC Group NV boosted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 53.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,151 shares of the company’s ...
Novartis1d
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...
TMCnet6d
CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders
CytoMed has generated the critical cell banks for the iPSC-derived hybrid of gamma delta T and Natural Killer cell technology and is currently undergoing process development into a potentially very ...
Pharmabiz1d
Novartis to buy Boston-based clinical-stage biopharma company, Anthos Therapeutics for up to $3.1 billion
Novartis to buy Boston-based clinical-stage biopharma company, Anthos Therapeutics for up to $3.1 billion: Basel Tuesday, February 11, 2025, 17:45 Hrs [IST] Novartis announced tha ...
CYTOMED THERAPEUTICS LIMITED: CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders
CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company") today released a letter to shareholders from the Chairman of the Company's Board ...
Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference
Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% ...
Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference
Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its AI-driven metagenomics platform. Metagenomi is harnessing the power of ...